Aldeyra Therapeutics (ALDX)

• Market cap: $331M
• 1 day: 1.29%
• 5 days: 3.18%
• 1 month: 11.31%
• 3 months: 2.23%
• 6 months: 145.98%
• Year to date: 5.56%
• 1 year: -0.36%
• 5 years: -22.39%
• 10 years: -15.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Employees: 8